MERLIN Diagnostika GmbH
MERLIN, the German corporation for microbiological diagnostics, develops and manufactures products for automated identification and antimicrobial susceptibility testing of bacteria and yeasts. These in-vitro diagnostics are being offered and used around the world in routine laboratories in the fields of human medicine as well as in veterinary medicine.
For more than 25 years, MERLIN is highly appreciated as partner in international research and study projects due to their well-informed, scientific support and their ability to produce individual, application-specific diagnostics even in small amounts.
MICRONAUT – synonym for identification and susceptibility testing
MICRONAUT is MERLIN’s trademarked product line for automated identification (ID) and antimicrobial susceptibility testing (AST) of bacteria and yeasts. MICRONAUT consists of a wide variety of diagnostics whose production is based on specific recipes: MERLIN’s technical know-how combined with highest flexibility specifies the optimal production volumes and manufacturing processes of both standardized and customized products in microtitration plates.
MICRONAUT ID systems – designed for special laboratory requirements
The identification of bacteria and yeasts with the MICRONAUT ID systems are based on biochemical reactions. In total, 400 clinical relevant species of bacteria and yeasts can be identified based on their biochemical profile. The ID system design reflects the requirements in routine diagnostics like Gram-positives, Gram-negatives, bacillus species, yeasts and others. This ingenious system of building blocks enables technicians to combine ID systems according to special laboratory requirements.
MICRONAUT MIC systems – approved methods combined with flexibility
The test principle of the MICRONAUT MIC system is based on phenotypic resistance detection by microbial growth in presence of antimicrobial agents. This broth microdilution procedure (BMD) is the international standard method and the worldwide accepted reference system for the determination of the minimum inhibitory concentration (MIC). These real MIC data represent the quantification of microbial resistance in terms of drug inhibitory concentrations and may indicate therapeutic options due to adaptions to standard dosage regiments.
Customized MICRONAUT MIC products provide highest flexibility due to an optional AST design derived from a pool of more than 200 antimicrobial agents (antibacterial agents/antifungal agents) worldwide in clinical use for human and veterinary medicine. This pool of antimicrobial agents is a growing body due to the incorporation of new drugs in the MERLIN product portfolio soon after launch or due to the introduction of new compounds for phenotypic detection of epidemiological relevant resistance mechanisms, e.g. for ß-lactamase detection.
MICRONAUT MIC systems – standardized even for special applications
MICRONAUT MIC plates are designed and standardized for covering an extended spectrum of organisms in microbiology including fastidious bacteria, anaerobic once, and fungi like yeasts or cryptococci. Other special applications comprise the phenotypic detection of epidemiological important resistance mechanisms like production of carbapenemases or cephalosporinases in multi drug resistant Gram-negative bacteria.
MICRONAUT Software – rapid reading, calculation and interpretation of MIC results
The MICRONAUT software is the core component of the entire, workflow-oriented MICRONAUT system. It allows the communication to external systems and the integration of external data like ID results from the MALDI-TOF analyzer. It also includes online communication with LIMS systems, device control, patient data management, calculation and interpretation of MIC results according to national and international standards (EUCAST, CLSI), generation of lab reports, and administration of QC data.
MICRONAUT – facing the threat of multi drug resistant microbes
The recent emergence of multi drug resistant bacteria have led to a major worldwide concern. Especially carbapenemase producing Gram-negative bacilli have rapidly spread all over the world including to Europe. These bacilli are a threat for infection control and for public health due to their rapid spread and clinical resistance to a wide range of antimicrobial agents.